Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 461.39 (+6.35), NVS: 103.58 (+1.01)
TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 34.60 (+0.20), NVS: 103.58 (+1.01)
Flexus Shows Other Immuno-Oncology Wannabes How It's Done
EP Vantage - Seeking Alpha - Wed Feb 25, 1:28PM CST
Deal making in the immuno-oncology space was always going to be a big theme of 2015, and Bristol-Myers Squibb ’s (NYSE: BMY ) moves yesterday – most notably the $800m it paid to secure Flexus Biosciences ’ preclinical...
MRK: 57.25 (-0.18), INCY: 93.81 (+1.53), NLNK: 55.38 (-0.33), BMY: 64.64 (+1.18)
Why Don't You Diversify Your Portfolio With Some European Blue Chips?
Gold Finder - at Seeking Alpha - Fri Jan 23, 9:50AM CST
UN: 43.24 (-0.03), HSBC: 44.69 (+0.15), GOOG: 540.01 (-0.77), T: 32.77 (+0.08), BRK.A: 215,211.00 (-311.80), NVS: 103.58 (+1.01)
Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 48.70 (-1.79), AKER: 4.60 (unch), WX: 39.12 (-0.49)